Lorazepam 4 mg IV Push for Status Epilepticus
Administer lorazepam 4 mg IV push slowly at 2 mg/min for status epilepticus in adults ≥18 years, as this is the FDA-approved and guideline-recommended dose. 1
Critical Administration Requirements
Before administering, ensure the following equipment and preparations are immediately available 1:
- Airway management equipment must be at bedside
- Mechanical ventilation capability ready for immediate use
- IV access established with vital sign monitoring
- Dilute lorazepam 1:1 with compatible solution (sterile water, normal saline, or D5W) before IV administration
- Inject slowly at maximum rate of 2 mg/min to minimize respiratory depression risk
Dosing Protocol for Status Epilepticus
Initial dose: 4 mg IV given over 2 minutes 1
- If seizures cease after initial dose, no additional lorazepam is required 1
- If seizures continue or recur after 10-15 minute observation period, administer second 4 mg dose slowly 1
- Experience with doses beyond 8 mg total is very limited 1
Evidence Supporting 4 mg Dosing
Underdosing lorazepam significantly increases progression to refractory status epilepticus. A 2023 study of 120 patients demonstrated that 87% of patients receiving <4 mg progressed to refractory status epilepticus compared to only 62% receiving the full 4 mg dose (p=0.03) 2. This supports adherence to the recommended 4 mg dose rather than weight-based dosing that results in underdosing.
The American Academy of Pediatrics guidelines note that lorazepam is typically used for initial IV treatment of status epilepticus, with pediatric dosing at 0.05-0.10 mg/kg (maximum 4 mg per dose) 3. The 4 mg maximum applies across age groups for adults.
Critical Safety Monitoring
Respiratory depression is the most important risk 1:
- Monitor continuously for respiratory depression, which may occur up to 30 minutes after the last dose 3
- Be prepared for immediate intubation if needed
- Respiratory depression may persist longer than the anticonvulsant effect 3
- Risk increases when combined with opioids or other CNS depressants 3
Additional monitoring requirements 1:
- Continuous vital signs
- Oxygen saturation
- Level of consciousness (excessive sedation may compound post-ictal state)
- Ensure no intra-arterial injection or perivascular extravasation
Flumazenil Availability
Have flumazenil available for life-threatening respiratory depression, but recognize it will reverse anticonvulsant effects and may precipitate seizure recurrence 3. This creates a clinical dilemma requiring careful risk-benefit assessment.
Common Pitfalls to Avoid
- Do not administer undiluted IV - must dilute 1:1 with compatible solution 1
- Do not exceed 2 mg/min injection rate - faster administration increases respiratory depression risk 1
- Do not use IM route as first-line - therapeutic levels are not reached as quickly as IV 1
- Do not assume single dose suffices - be prepared to administer second 4 mg dose if seizures persist after 10-15 minutes 1
Special Populations
Elderly patients (>50 years): No dose adjustment needed for acute administration, but expect more profound and prolonged sedation 1
Hepatic/renal disease: No acute dose adjustment required, though caution with repeated dosing in renal disease 1